Skip to content

Fertility Preservation Research

Fertility preservation is the process of saving or protecting eggs, sperm, or reproductive tissue so that a person can use them to have biological children in the future. At CRH our clinicians are consistently looking for ways to improve the fertility preservation process. They are examining patients with breast cancer who wish to preserve their eggs before undergoing treatment for cancer. Our clinicians are at the forefront of the field; seeing patients with other forms of cancer as well as transgender individuals who wish to preserve their eggs to have biological children after undergoing treatment. Patients continue to offer their participation in our studies to better understand the effects of different medical/surgical treatments on the reproductive system.

Fertility Preservation Studies

Status: Active, Enrolling

BRIOR Study | Impact of Local Radiotherapy to the Breast on Ovarian Reserve in Premenopausal Women with Early-Stage Breast Cancer

This study aims to prospectively assess the impact of distant effects from breast radiation on ovarian reserve. We will determine ovarian reserve through blood measurements of Anti-Müllerian Hormone (AMH), a relatively new and reliable serum biomarker of ovarian reserve that has already been incorporated into the standard practice of reproductive endocrinology and infertility.

You may be eligible if you are: female (or assigned female at birth), aged 18-45, and diagnosed with in-situ breast cancer or stage 1 breast cancer

Headshot of Mitchell Rosen, MD - Principal Investigator
Mitchell Rosen, MD
Principal Investigator
Headshot of Flor Juarez-Hernandez - Research Coordinator
Flor Juarez-Hernandez
Research Coordinator
Headshot of Nikolaus Lenhart - Research Coordinator
Nikolaus Lenhart
Research Coordinator

Status: Active, Enrolling

MDM Study | Medical Decision making and Fertility Preservation

Through electronic surveys, this study aims to prospectively understand the wide range of individual and systematic variables that impact a woman's ability and interest in pursuing fertility preservation prior to cancer treatment. We will also monitor ovarian reserve through blood measurements and ultrasounds pre and post treatment to better understand the specific impact of the large number of cancer treatments patients undergo.

You may be eligible if you are: female (or assigned female at birth), aged 18-45, newly diagnosed with cancer

Headshot of Mitchell Rosen, MD - Principal Investigator
Mitchell Rosen, MD
Principal Investigator
Headshot of Flor Juarez-Hernandez - Research Coordinator
Flor Juarez-Hernandez
Research Coordinator
Headshot of Nikolaus Lenhart - Research Coordinator
Nikolaus Lenhart
Research Coordinator
Status: Active, Enrolling

TALES Trial | Fertility Preservation using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Letrozole plus gonadotropin, and Tamoxifen plus gonadotropin, are two methods currently used worldwide in ovarian stimulation cycles for fertility preservation in patients with estrogen-receptor-positive breast cancer. Improved knowledge about the efficacy of these medications, with regard to oocyte yield, has the potential to significantly improve quality of life in reproductive-age breast cancer survivors.

Headshot of Mitchell Rosen, MD - Principal Investigator
Mitchell Rosen, MD
Principal Investigator
Headshot of Flor Juarez-Hernandez - Research Coordinator
Flor Juarez-Hernandez
Research Coordinator
Headshot of Nikolaus Lenhart - Research Coordinator
Nikolaus Lenhart
Research Coordinator